You are here

Article Text

Article menu

Download PDFPDF

18F-FDG-PET-positive adrenal tumour
Free
  1. Maiko Kakita-Kobayashi1,
  2. Takeshi Usui2,
  3. Hironobu Sasano3,
  4. Akira Shimatsu2
  1. 1Department of Endocrinology and Metabolism, National Hospital Organization Kyoto Medical Center, Kyoto, Japan
  2. 2Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto, Japan
  3. 3Department of Pathology, Tohoku University School of Medicine, Sendai, Japan
  1. Correspondence to Dr Takeshi Usui, tusui{at}kuhp.kyoto-u.ac.jp

https://doi.org/10.1136/bcr-2015-209379

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Description

    A 36-year-old woman presented with a history of sudden back pain. A CT scan showed a retroperitoneal mass (60×38 mm) in the vicinity of the superior pole of the left kidney (figure 1A). She had no apparent signs of Cushing's syndrome. General examination, including complete blood count, blood chemistry, chest X-ray and ECG were all unremarkable. Endocrinological examination, including basal adrenocorticotropic hormone and cortisol levels, was also unremarkable. MRI was performed to characterise the lesion further, and confirmed the absence of fat within the solid lesion (figure 1B). T2-weighted MRI showed mild high intensity (figure 1C). 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) showed intense FDG uptake in the mass (figure 2). Maximum standardised uptake value was 14.2. There was no uptake in other lesions. A left adrenalectomy was performed through a left subcostal incision after assessing the probable size of the malignancy. The histopathological analysis revealed that the tumour comprised eosinophilic cells that were diffusely immunopositive for mitochondrial antigen and steroidogenic factor 1 immunopositivity. We therefore diagnosed this tumour as an adrenocortical oncocytoma. Although the oncocytoma showed nuclear atypia, diffuse architecture and clear cells merely comprising less than 25% of the tumour, it was classified as ‘benign’ according to the Lin-Weiss Bisceglia criteria.1 Oncocytomas arising in the retroperitoneal heterotopic adrenal tissue are very rare.2 High FDG uptake in adrenocortical oncocytomas is suggested to be due to the presence of numerous intracellular mitochondria.3 At 2 years after surgery, FDG-PET showed no recurrence or metastasis.

    Learning points

    • Oncocytomas in most cases are benign epithelial tumours composed of eosinophilic cells.

    • Adrenocortical oncocytomas are very rare adrenal tumours.

    • Adrenal oncocytomas should be considered in cases of 18F-fluorodeoxyglucose positron emission tomography-positive adrenal tumour.

    Figure 1
    Figure 1

    (A) Preoperative axial contrast-enhanced CT findings. The left adrenal mass is heterogeneously enhanced in cumulativeness. (B) Preoperative axial MRI findings. Opposed phase in the chemical shift imaging showing the absence of fat within the solid lesion. (C) T2-weighted MRI showing heterogeneous and mild high intensity.

    Figure 2
    Figure 2

    Coronal (A) and axial (B) 18F-fluorodeoxyglucose (FDG) positron emission tomography showing remarkable FDG uptake in the left adrenal mass.

    References

    1. ↵
      1. Bisceglia M,
      2. Ludovico O,
      3. Di Mattia A, et al
      . Adrenocortical oncocytic tumors: report of 10 cases and review of the literature. Int J Surg Pathol 2004;12:231–43.
      OpenUrlAbstract/FREE Full Text
    2. ↵
      1. Mearini L,
      2. Del Sordo R,
      3. Costantini E, et al
      . Adrenal oncocytic neoplasm: a systematic review. Urol Int 2013;91:125–33.
      OpenUrlCrossRefPubMed
    3. ↵
      1. Kim DJ,
      2. Chung JJ,
      3. Ryu YH, et al
      . Adrenocortical oncocytoma displaying intense activity on 18F-FDG-PET: a case report and a literature review. Ann Nucl Med 2008;22:821–4.
      OpenUrlCrossRefPubMed
    View Abstract

    Footnotes

    • Competing interests None.

    • Patient consent Obtained.

    • Provenance and peer review Not commissioned; externally peer reviewed.